跳至主要内容
临床试验/NCT04258969
NCT04258969撤回不适用

Evaluating the Feasibility of Pedaling at a Low-moderate Intensity During Chemotherapy Infusions in Colorectal Cancer Patients.

Rush University Medical Center2 个研究点 分布在 1 个国家开始时间: 2020年1月11日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
试验地点
2
主要终点
Feasibility of Pedaling Concurrent to Chemotherapy Infusion

研究概览

简要总结

The purpose of this study is to evaluate the feasibility of completing a low-moderate intensity pedaling session concurrent to chemotherapy treatment for colorectal cancer. Secondary objectives for this study consist of evaluating the role of pedaling on sarcopenia rates, quality of life markers, chemotherapy side effects, rate of hospital admissions, and treatment delays.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with diagnosed colon or rectal cancer with previous surgical intervention and planned intravenous chemotherapy treatment (FOLFOX or FOLFIRI).
  • ECOG Performance Status of Grade 0-2.

排除标准

  • Limited functional status, demonstrated by an ECOG Performance Status of Grade 3-
  • Severe cardiac history or comorbidities (i.e. have a cardiac defibrillator or have a history of heart failure, clinically significant aortic stenosis, cardiac arrest, uncontrolled angina, uncontrolled arrhythmias, major heart surgery, stroke, or pulmonary embolus).
  • Chest pain or severe shortness of breath at rest or with physical activity.
  • Orthopedic impediments to exercise (i.e. joint immobility or lower extremity lymphedema).
  • Limitations to sustained exercise (i.e. bone metastases in the femur neck).
  • Severe arthritis (i.e. osteoarthritis or rheumatoid arthritis).

结局指标

主要结局

Feasibility of Pedaling Concurrent to Chemotherapy Infusion

时间窗: 12-24 weeks

The number of completed pedaling sessions as well as the ability of patients to meet goal pedaling intensities will be evaluated.

次要结局

  • Hospital Admission Rates(12-24 weeks)
  • Quality of Life Scores(12-24 weeks)
  • Sarcopenia Rates(12-24 weeks)
  • Symptom Severity(12-24 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验